BPP-5a produces a potent and long-lasting NO-dependent antihypertensive effect
Authors:
- Carlos Henrique XavierCXCarlos Henrique Xavier
- Fabiana Costa FragaFFFabiana Costa Fraga
- Roberto Queiroga LautnerRLRoberto Queiroga Lautner
- Juliano Rodrigo GuerreiroJGJuliano Rodrigo Guerreiro
- Leonor Tapias MachadoLMLeonor Tapias Machado
- Elizabeth Pereira MendesEMElizabeth Pereira Mendes
- Andônio Carlos Martins de CamargoACAndônio Carlos Martins de Camargo
- Robson Augusto Souza SantosRobson Augusto Souza Santos
Open Access
- 27 October 2011
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Cardiovascular Disease
- Vol. 5 (6) , 281-295
Abstract
Background: The bradykinin potentiating peptides (BPPs) are oligopeptides found in different animal venoms. BPPs isolated from Bothrops jararaca venom were the first natural inhibitors described for somatic angiotensin I-converting enzyme (ACE). They were used in the structural modeling for captopril development, a classical ACE inhibitor widely used to treat human hypertension. Methods: We evaluated the effect of BPP-5a on cardiovascular parameters of conscious Wistar (WTs) and spontaneously hypertensive rats (SHRs). Results: In SHR, BPP-5a showed potent cardiovascular effects, at doses ranging from 0.47 to 710 nmol/kg. The maximal changes in mean arterial pressure (MAP) and heart rate (HR) were found at the dose of 2.37 nmol/kg (Δ MAP: −38 ± 4 mmHg, p < 0.01; Δ HR: −71 ± 17 bpm, p < 0.05). Reductions in MAP and HR occurred throughout 6 hours of post-injection period. In contrast to active site-directed ACE inhibitors, no ACE inhibition, evaluated by the Ang I pressor effect, or bradykinin potentiation was observed during the antihypertensive effect of the pentapeptide. In vitro assays showed no effects of BPP-5a upon argininosuccinate synthetase and B1, B2, AT1, AT2 or Mas receptors. Ex vivo assays showed that BPP-5a induced endothelium-dependent vasorelaxation in isolated aortic rings of SHRs and WTs. Conclusions: Although the BPP-5a is considered an ACE inhibitor, our results indicate that its antihypertensive effect is exerted via a unique target, a nitric-oxide-dependent mechanism.Keywords
This publication has 40 references indexed in Scilit:
- Angiotensin I–Converting Enzyme Inhibitors Are Allosteric Enhancers of Kinin B1 and B2 Receptor FunctionHypertension, 2010
- Argininosuccinate Synthetase Is a Functional Target for a Snake Venom Anti-hypertensive PeptideJournal of Biological Chemistry, 2009
- Captopril as a Potential Inhibitor of Lung Tumor Growth and MetastasisAnnals of the New York Academy of Sciences, 2008
- Muscarinic Receptor Knockout Mice Confirm Involvement of M3 Receptor in Endothelium-dependent Vasodilatation in Mouse ArteriesJournal of Cardiovascular Pharmacology, 2008
- Evidence for Mas-Mediated Bradykinin Potentiation by the Angiotensin-(1-7) Nonpeptide Mimic AVE 0991 in Normotensive RatsHypertension, 2007
- Inhibition of homogeneous angiotensin-converting enzyme of rabbit lung by synthetic venom peptides of Bothrops jararacaBiochimica et Biophysica Acta (BBA) - Enzymology, 1973
- Action of bradykinin potentiating factor (BPF) and dimercaprol (BAL) on the responses to bradykinin of isolated preparations of rat intestinesBritish Journal of Pharmacology, 1971
- Isolation of bradykinin-potentiating peptides from Bothrops jararaca venomBiochemistry, 1970
- Activity of Various Fractions of Bradykinin Potentiating Factor against Angiotensin I Converting EnzymeNature, 1970
- A BRADYKININ‐POTENTIATING FACTOR (BPF) PRESENT IN THE VENOM OF BOTHROPS JARARACABritish Journal of Pharmacology and Chemotherapy, 1965